CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
溶瘤病毒T-Vec应用于肿瘤治疗的临床研究进展
Authors
吴婷
姚星妹
潘莉莉
Publication date
25 April 2019
Publisher
Abstract
T-Vec(talimogene laherparepvec)是由Ⅰ型单纯疱疹病毒(HSV-1)改造而来的一种溶瘤病毒,能够选择性地在恶性肿瘤细胞中复制而不伤及其他正常细胞。T-Vec在治疗晚期黑色素瘤患者的Ⅲ期临床试验中显示出良好的安全性和肿瘤治疗效果,已于2015年经美国FDA批准用于治疗晚期黑色素瘤。为了提高T-Vec的疗效,扩大其应用范围,T-Vec联合其他抗肿瘤疗法以及应用于其他肿瘤的临床试验仍在陆续开展。近期,T-Vec联合免疫检查点抑制剂在治疗晚期黑色素瘤的临床试验中取得新进展,临床数据显示T-Vec联合疗法具有更强的抗肿瘤活性。此外,T-Vec在治疗头颈癌、胰腺癌、肝癌等肿瘤的临床研究中也取得了一定进展。本文对近年来T-Vec治疗肿瘤的临床试验的相关研究进展做一综述。分子疫苗学和分子诊断学国家重点实验室资助项目(No.2016ZY005);;厦门大学国家传染病诊断试剂与疫苗工程技术研究中心自主项目(No.XDHT2016494A)~
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Xiamen University Institutional Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:dspace.xmu.edu.cn:2288/177...
Last time updated on 20/11/2020